Review



parental 786 o  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    ATCC parental 786 o
    Growth‑inhibitory effect of cabozantinib. (A) Dose-response cell viability after 48 h cabozantinib treatment <t>in</t> <t>786-O</t> and Caki-1 cells. Values represent mean ± standard deviation (SD) (n=4); *p<0.01 vs. vehicle. (B) Immunoblot analysis of total MET and phospho-MET (Y1234/1235) in parental (Par) and chronically treated (Chr) cells, with or without cabozantinib treatment. Cabozantinib robustly suppressed phospho-MET in both Par and Chr states of both cell lines. β-actin serves as a loading control. (C) Time-course viability (24-72 h) of Par and Chr 786-O cells. (D) Time-course viability (24-72 h) of Par and Chr Caki-1 cells. Cab: acute cabozantinib-treated; Par: parental; Chr: chronically cabozantinib-treated cells (>4 months). *p<0.05; **p<0.01. Statistical significance was determined using an unpaired two-tailed Student’s t-test.
    Parental 786 O, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 2346 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/parental 786 o/product/ATCC
    Average 99 stars, based on 2346 article reviews
    parental 786 o - by Bioz Stars, 2026-03
    99/100 stars

    Images

    1) Product Images from "Timescale-dependent Phosphoproteomic Remodeling and Motility-associated Adaptation under Chronic Cabozantinib Exposure in Renal Cell Carcinoma"

    Article Title: Timescale-dependent Phosphoproteomic Remodeling and Motility-associated Adaptation under Chronic Cabozantinib Exposure in Renal Cell Carcinoma

    Journal: Cancer Genomics & Proteomics

    doi: 10.21873/cgp.20576

    Growth‑inhibitory effect of cabozantinib. (A) Dose-response cell viability after 48 h cabozantinib treatment in 786-O and Caki-1 cells. Values represent mean ± standard deviation (SD) (n=4); *p<0.01 vs. vehicle. (B) Immunoblot analysis of total MET and phospho-MET (Y1234/1235) in parental (Par) and chronically treated (Chr) cells, with or without cabozantinib treatment. Cabozantinib robustly suppressed phospho-MET in both Par and Chr states of both cell lines. β-actin serves as a loading control. (C) Time-course viability (24-72 h) of Par and Chr 786-O cells. (D) Time-course viability (24-72 h) of Par and Chr Caki-1 cells. Cab: acute cabozantinib-treated; Par: parental; Chr: chronically cabozantinib-treated cells (>4 months). *p<0.05; **p<0.01. Statistical significance was determined using an unpaired two-tailed Student’s t-test.
    Figure Legend Snippet: Growth‑inhibitory effect of cabozantinib. (A) Dose-response cell viability after 48 h cabozantinib treatment in 786-O and Caki-1 cells. Values represent mean ± standard deviation (SD) (n=4); *p<0.01 vs. vehicle. (B) Immunoblot analysis of total MET and phospho-MET (Y1234/1235) in parental (Par) and chronically treated (Chr) cells, with or without cabozantinib treatment. Cabozantinib robustly suppressed phospho-MET in both Par and Chr states of both cell lines. β-actin serves as a loading control. (C) Time-course viability (24-72 h) of Par and Chr 786-O cells. (D) Time-course viability (24-72 h) of Par and Chr Caki-1 cells. Cab: acute cabozantinib-treated; Par: parental; Chr: chronically cabozantinib-treated cells (>4 months). *p<0.05; **p<0.01. Statistical significance was determined using an unpaired two-tailed Student’s t-test.

    Techniques Used: Standard Deviation, Western Blot, Control, Two Tailed Test

    Quantitative phosphoproteomic profiling of acute and chronic cabozantinib exposure in 786-O cells. (A) Volcano plot showing significantly regulated phosphosites in the Cab/Par comparison after 48 h acute treatment (FDR <0.01, s0=0.1). Red and green dots indicate significantly upregulated and downregulated phosphosites, respectively; grey dots indicate non-significantly regulated phosphosites. (B) Volcano plot showing significantly regulated phosphosites in the Chr/Par comparison after >4 months of chronic exposure (FDR <0.01, s0=0.1). Color coding is as in (A). (C) Volcano plot directly comparing the two drug-treated states (Chr vs. Cab), highlighting differentially regulated phosphosites using the same color scheme (D) KEGG pathway enrichment for phosphoproteins significantly regulated in the Cab/Par condition. (E) Reactome pathway enrichment for phosphoproteins significantly regulated in the Cab/Par condition. (F) KEGG pathway enrichment for phosphoproteins significantly regulated in the Chr/Par condition. (G) Reactome pathway enrichment for phosphoproteins significantly regulated in the Chr/Par condition. Phosphosite regulation was determined from log2-transformed ratio using permutation-based statistics. Enrichment analyses were performed separately for Cab/Par and Chr/Par contrasts. Pathway enrichment analyses were performed using significantly regulated phosphosites as the input list, with all quantified phosphoproteins used as the background set.
    Figure Legend Snippet: Quantitative phosphoproteomic profiling of acute and chronic cabozantinib exposure in 786-O cells. (A) Volcano plot showing significantly regulated phosphosites in the Cab/Par comparison after 48 h acute treatment (FDR <0.01, s0=0.1). Red and green dots indicate significantly upregulated and downregulated phosphosites, respectively; grey dots indicate non-significantly regulated phosphosites. (B) Volcano plot showing significantly regulated phosphosites in the Chr/Par comparison after >4 months of chronic exposure (FDR <0.01, s0=0.1). Color coding is as in (A). (C) Volcano plot directly comparing the two drug-treated states (Chr vs. Cab), highlighting differentially regulated phosphosites using the same color scheme (D) KEGG pathway enrichment for phosphoproteins significantly regulated in the Cab/Par condition. (E) Reactome pathway enrichment for phosphoproteins significantly regulated in the Cab/Par condition. (F) KEGG pathway enrichment for phosphoproteins significantly regulated in the Chr/Par condition. (G) Reactome pathway enrichment for phosphoproteins significantly regulated in the Chr/Par condition. Phosphosite regulation was determined from log2-transformed ratio using permutation-based statistics. Enrichment analyses were performed separately for Cab/Par and Chr/Par contrasts. Pathway enrichment analyses were performed using significantly regulated phosphosites as the input list, with all quantified phosphoproteins used as the background set.

    Techniques Used: Comparison, Phospho-proteomics, Transformation Assay

    Migration, invasion, and signaling adaptations in 786-O cells under chronic cabozantinib exposure. (A) Transwell migration assay of Par and Chr 786-O cells. Migrated cells were fixed, crystal-violet stained, and quantified using ImageJ. (B) Matrigel invasion assay performed using the same cell model and quantification workflow as in (A). Invasion was assessed following 6 h incubation through Matrigel-coated inserts. (C) Immunoblot analysis of selected signaling nodes in Par and Chr 786-O cells, including MET, phospho-MET (Y1234/1235), ERK1/2, phospho-ERK, c-Jun, phospho-c-Jun (S63), HSPB1, and phospho-HSPB1 (S82). β-actin served as loading control. (D) Network representation of Chr-associated phosphosites mapped to adhesion- and stress-associated signaling modules based on the annotation-enrichment analysis. Data are shown as mean ± standard deviation (SD) from three independent experiments. Statistical significance was determined using an unpaired two-tailed Student’s t-test; #p<0.05; *p<0.01.
    Figure Legend Snippet: Migration, invasion, and signaling adaptations in 786-O cells under chronic cabozantinib exposure. (A) Transwell migration assay of Par and Chr 786-O cells. Migrated cells were fixed, crystal-violet stained, and quantified using ImageJ. (B) Matrigel invasion assay performed using the same cell model and quantification workflow as in (A). Invasion was assessed following 6 h incubation through Matrigel-coated inserts. (C) Immunoblot analysis of selected signaling nodes in Par and Chr 786-O cells, including MET, phospho-MET (Y1234/1235), ERK1/2, phospho-ERK, c-Jun, phospho-c-Jun (S63), HSPB1, and phospho-HSPB1 (S82). β-actin served as loading control. (D) Network representation of Chr-associated phosphosites mapped to adhesion- and stress-associated signaling modules based on the annotation-enrichment analysis. Data are shown as mean ± standard deviation (SD) from three independent experiments. Statistical significance was determined using an unpaired two-tailed Student’s t-test; #p<0.05; *p<0.01.

    Techniques Used: Migration, Transwell Migration Assay, Staining, Invasion Assay, Incubation, Western Blot, Control, Standard Deviation, Two Tailed Test



    Similar Products

    99
    ATCC parental 786 o
    Growth‑inhibitory effect of cabozantinib. (A) Dose-response cell viability after 48 h cabozantinib treatment <t>in</t> <t>786-O</t> and Caki-1 cells. Values represent mean ± standard deviation (SD) (n=4); *p<0.01 vs. vehicle. (B) Immunoblot analysis of total MET and phospho-MET (Y1234/1235) in parental (Par) and chronically treated (Chr) cells, with or without cabozantinib treatment. Cabozantinib robustly suppressed phospho-MET in both Par and Chr states of both cell lines. β-actin serves as a loading control. (C) Time-course viability (24-72 h) of Par and Chr 786-O cells. (D) Time-course viability (24-72 h) of Par and Chr Caki-1 cells. Cab: acute cabozantinib-treated; Par: parental; Chr: chronically cabozantinib-treated cells (>4 months). *p<0.05; **p<0.01. Statistical significance was determined using an unpaired two-tailed Student’s t-test.
    Parental 786 O, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/parental 786 o/product/ATCC
    Average 99 stars, based on 1 article reviews
    parental 786 o - by Bioz Stars, 2026-03
    99/100 stars
      Buy from Supplier

    93
    MedChemExpress parental 786 o cells
    Growth‑inhibitory effect of cabozantinib. (A) Dose-response cell viability after 48 h cabozantinib treatment <t>in</t> <t>786-O</t> and Caki-1 cells. Values represent mean ± standard deviation (SD) (n=4); *p<0.01 vs. vehicle. (B) Immunoblot analysis of total MET and phospho-MET (Y1234/1235) in parental (Par) and chronically treated (Chr) cells, with or without cabozantinib treatment. Cabozantinib robustly suppressed phospho-MET in both Par and Chr states of both cell lines. β-actin serves as a loading control. (C) Time-course viability (24-72 h) of Par and Chr 786-O cells. (D) Time-course viability (24-72 h) of Par and Chr Caki-1 cells. Cab: acute cabozantinib-treated; Par: parental; Chr: chronically cabozantinib-treated cells (>4 months). *p<0.05; **p<0.01. Statistical significance was determined using an unpaired two-tailed Student’s t-test.
    Parental 786 O Cells, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/parental 786 o cells/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    parental 786 o cells - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    99
    ATCC parental cell lines
    Growth‑inhibitory effect of cabozantinib. (A) Dose-response cell viability after 48 h cabozantinib treatment <t>in</t> <t>786-O</t> and Caki-1 cells. Values represent mean ± standard deviation (SD) (n=4); *p<0.01 vs. vehicle. (B) Immunoblot analysis of total MET and phospho-MET (Y1234/1235) in parental (Par) and chronically treated (Chr) cells, with or without cabozantinib treatment. Cabozantinib robustly suppressed phospho-MET in both Par and Chr states of both cell lines. β-actin serves as a loading control. (C) Time-course viability (24-72 h) of Par and Chr 786-O cells. (D) Time-course viability (24-72 h) of Par and Chr Caki-1 cells. Cab: acute cabozantinib-treated; Par: parental; Chr: chronically cabozantinib-treated cells (>4 months). *p<0.05; **p<0.01. Statistical significance was determined using an unpaired two-tailed Student’s t-test.
    Parental Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/parental cell lines/product/ATCC
    Average 99 stars, based on 1 article reviews
    parental cell lines - by Bioz Stars, 2026-03
    99/100 stars
      Buy from Supplier

    93
    MedChemExpress pazopanib resistant cell line 786 o pr establishment parental 786 o cells
    Growth‑inhibitory effect of cabozantinib. (A) Dose-response cell viability after 48 h cabozantinib treatment <t>in</t> <t>786-O</t> and Caki-1 cells. Values represent mean ± standard deviation (SD) (n=4); *p<0.01 vs. vehicle. (B) Immunoblot analysis of total MET and phospho-MET (Y1234/1235) in parental (Par) and chronically treated (Chr) cells, with or without cabozantinib treatment. Cabozantinib robustly suppressed phospho-MET in both Par and Chr states of both cell lines. β-actin serves as a loading control. (C) Time-course viability (24-72 h) of Par and Chr 786-O cells. (D) Time-course viability (24-72 h) of Par and Chr Caki-1 cells. Cab: acute cabozantinib-treated; Par: parental; Chr: chronically cabozantinib-treated cells (>4 months). *p<0.05; **p<0.01. Statistical significance was determined using an unpaired two-tailed Student’s t-test.
    Pazopanib Resistant Cell Line 786 O Pr Establishment Parental 786 O Cells, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pazopanib resistant cell line 786 o pr establishment parental 786 o cells/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    pazopanib resistant cell line 786 o pr establishment parental 786 o cells - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    90
    Broad Institute Inc 786-o parental
    Growth‑inhibitory effect of cabozantinib. (A) Dose-response cell viability after 48 h cabozantinib treatment <t>in</t> <t>786-O</t> and Caki-1 cells. Values represent mean ± standard deviation (SD) (n=4); *p<0.01 vs. vehicle. (B) Immunoblot analysis of total MET and phospho-MET (Y1234/1235) in parental (Par) and chronically treated (Chr) cells, with or without cabozantinib treatment. Cabozantinib robustly suppressed phospho-MET in both Par and Chr states of both cell lines. β-actin serves as a loading control. (C) Time-course viability (24-72 h) of Par and Chr 786-O cells. (D) Time-course viability (24-72 h) of Par and Chr Caki-1 cells. Cab: acute cabozantinib-treated; Par: parental; Chr: chronically cabozantinib-treated cells (>4 months). *p<0.05; **p<0.01. Statistical significance was determined using an unpaired two-tailed Student’s t-test.
    786 O Parental, supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/786-o parental/product/Broad Institute Inc
    Average 90 stars, based on 1 article reviews
    786-o parental - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    99
    ATCC 786 o parental
    Growth‑inhibitory effect of cabozantinib. (A) Dose-response cell viability after 48 h cabozantinib treatment <t>in</t> <t>786-O</t> and Caki-1 cells. Values represent mean ± standard deviation (SD) (n=4); *p<0.01 vs. vehicle. (B) Immunoblot analysis of total MET and phospho-MET (Y1234/1235) in parental (Par) and chronically treated (Chr) cells, with or without cabozantinib treatment. Cabozantinib robustly suppressed phospho-MET in both Par and Chr states of both cell lines. β-actin serves as a loading control. (C) Time-course viability (24-72 h) of Par and Chr 786-O cells. (D) Time-course viability (24-72 h) of Par and Chr Caki-1 cells. Cab: acute cabozantinib-treated; Par: parental; Chr: chronically cabozantinib-treated cells (>4 months). *p<0.05; **p<0.01. Statistical significance was determined using an unpaired two-tailed Student’s t-test.
    786 O Parental, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/786 o parental/product/ATCC
    Average 99 stars, based on 1 article reviews
    786 o parental - by Bioz Stars, 2026-03
    99/100 stars
      Buy from Supplier

    Image Search Results


    Growth‑inhibitory effect of cabozantinib. (A) Dose-response cell viability after 48 h cabozantinib treatment in 786-O and Caki-1 cells. Values represent mean ± standard deviation (SD) (n=4); *p<0.01 vs. vehicle. (B) Immunoblot analysis of total MET and phospho-MET (Y1234/1235) in parental (Par) and chronically treated (Chr) cells, with or without cabozantinib treatment. Cabozantinib robustly suppressed phospho-MET in both Par and Chr states of both cell lines. β-actin serves as a loading control. (C) Time-course viability (24-72 h) of Par and Chr 786-O cells. (D) Time-course viability (24-72 h) of Par and Chr Caki-1 cells. Cab: acute cabozantinib-treated; Par: parental; Chr: chronically cabozantinib-treated cells (>4 months). *p<0.05; **p<0.01. Statistical significance was determined using an unpaired two-tailed Student’s t-test.

    Journal: Cancer Genomics & Proteomics

    Article Title: Timescale-dependent Phosphoproteomic Remodeling and Motility-associated Adaptation under Chronic Cabozantinib Exposure in Renal Cell Carcinoma

    doi: 10.21873/cgp.20576

    Figure Lengend Snippet: Growth‑inhibitory effect of cabozantinib. (A) Dose-response cell viability after 48 h cabozantinib treatment in 786-O and Caki-1 cells. Values represent mean ± standard deviation (SD) (n=4); *p<0.01 vs. vehicle. (B) Immunoblot analysis of total MET and phospho-MET (Y1234/1235) in parental (Par) and chronically treated (Chr) cells, with or without cabozantinib treatment. Cabozantinib robustly suppressed phospho-MET in both Par and Chr states of both cell lines. β-actin serves as a loading control. (C) Time-course viability (24-72 h) of Par and Chr 786-O cells. (D) Time-course viability (24-72 h) of Par and Chr Caki-1 cells. Cab: acute cabozantinib-treated; Par: parental; Chr: chronically cabozantinib-treated cells (>4 months). *p<0.05; **p<0.01. Statistical significance was determined using an unpaired two-tailed Student’s t-test.

    Article Snippet: Parental 786-O and Caki-1 renal cell carcinoma cell lines were obtained from ATCC (Manassas, VA, USA) and cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum at 37°C in a humidified atmosphere containing 5% CO 2 .

    Techniques: Standard Deviation, Western Blot, Control, Two Tailed Test

    Quantitative phosphoproteomic profiling of acute and chronic cabozantinib exposure in 786-O cells. (A) Volcano plot showing significantly regulated phosphosites in the Cab/Par comparison after 48 h acute treatment (FDR <0.01, s0=0.1). Red and green dots indicate significantly upregulated and downregulated phosphosites, respectively; grey dots indicate non-significantly regulated phosphosites. (B) Volcano plot showing significantly regulated phosphosites in the Chr/Par comparison after >4 months of chronic exposure (FDR <0.01, s0=0.1). Color coding is as in (A). (C) Volcano plot directly comparing the two drug-treated states (Chr vs. Cab), highlighting differentially regulated phosphosites using the same color scheme (D) KEGG pathway enrichment for phosphoproteins significantly regulated in the Cab/Par condition. (E) Reactome pathway enrichment for phosphoproteins significantly regulated in the Cab/Par condition. (F) KEGG pathway enrichment for phosphoproteins significantly regulated in the Chr/Par condition. (G) Reactome pathway enrichment for phosphoproteins significantly regulated in the Chr/Par condition. Phosphosite regulation was determined from log2-transformed ratio using permutation-based statistics. Enrichment analyses were performed separately for Cab/Par and Chr/Par contrasts. Pathway enrichment analyses were performed using significantly regulated phosphosites as the input list, with all quantified phosphoproteins used as the background set.

    Journal: Cancer Genomics & Proteomics

    Article Title: Timescale-dependent Phosphoproteomic Remodeling and Motility-associated Adaptation under Chronic Cabozantinib Exposure in Renal Cell Carcinoma

    doi: 10.21873/cgp.20576

    Figure Lengend Snippet: Quantitative phosphoproteomic profiling of acute and chronic cabozantinib exposure in 786-O cells. (A) Volcano plot showing significantly regulated phosphosites in the Cab/Par comparison after 48 h acute treatment (FDR <0.01, s0=0.1). Red and green dots indicate significantly upregulated and downregulated phosphosites, respectively; grey dots indicate non-significantly regulated phosphosites. (B) Volcano plot showing significantly regulated phosphosites in the Chr/Par comparison after >4 months of chronic exposure (FDR <0.01, s0=0.1). Color coding is as in (A). (C) Volcano plot directly comparing the two drug-treated states (Chr vs. Cab), highlighting differentially regulated phosphosites using the same color scheme (D) KEGG pathway enrichment for phosphoproteins significantly regulated in the Cab/Par condition. (E) Reactome pathway enrichment for phosphoproteins significantly regulated in the Cab/Par condition. (F) KEGG pathway enrichment for phosphoproteins significantly regulated in the Chr/Par condition. (G) Reactome pathway enrichment for phosphoproteins significantly regulated in the Chr/Par condition. Phosphosite regulation was determined from log2-transformed ratio using permutation-based statistics. Enrichment analyses were performed separately for Cab/Par and Chr/Par contrasts. Pathway enrichment analyses were performed using significantly regulated phosphosites as the input list, with all quantified phosphoproteins used as the background set.

    Article Snippet: Parental 786-O and Caki-1 renal cell carcinoma cell lines were obtained from ATCC (Manassas, VA, USA) and cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum at 37°C in a humidified atmosphere containing 5% CO 2 .

    Techniques: Comparison, Phospho-proteomics, Transformation Assay

    Migration, invasion, and signaling adaptations in 786-O cells under chronic cabozantinib exposure. (A) Transwell migration assay of Par and Chr 786-O cells. Migrated cells were fixed, crystal-violet stained, and quantified using ImageJ. (B) Matrigel invasion assay performed using the same cell model and quantification workflow as in (A). Invasion was assessed following 6 h incubation through Matrigel-coated inserts. (C) Immunoblot analysis of selected signaling nodes in Par and Chr 786-O cells, including MET, phospho-MET (Y1234/1235), ERK1/2, phospho-ERK, c-Jun, phospho-c-Jun (S63), HSPB1, and phospho-HSPB1 (S82). β-actin served as loading control. (D) Network representation of Chr-associated phosphosites mapped to adhesion- and stress-associated signaling modules based on the annotation-enrichment analysis. Data are shown as mean ± standard deviation (SD) from three independent experiments. Statistical significance was determined using an unpaired two-tailed Student’s t-test; #p<0.05; *p<0.01.

    Journal: Cancer Genomics & Proteomics

    Article Title: Timescale-dependent Phosphoproteomic Remodeling and Motility-associated Adaptation under Chronic Cabozantinib Exposure in Renal Cell Carcinoma

    doi: 10.21873/cgp.20576

    Figure Lengend Snippet: Migration, invasion, and signaling adaptations in 786-O cells under chronic cabozantinib exposure. (A) Transwell migration assay of Par and Chr 786-O cells. Migrated cells were fixed, crystal-violet stained, and quantified using ImageJ. (B) Matrigel invasion assay performed using the same cell model and quantification workflow as in (A). Invasion was assessed following 6 h incubation through Matrigel-coated inserts. (C) Immunoblot analysis of selected signaling nodes in Par and Chr 786-O cells, including MET, phospho-MET (Y1234/1235), ERK1/2, phospho-ERK, c-Jun, phospho-c-Jun (S63), HSPB1, and phospho-HSPB1 (S82). β-actin served as loading control. (D) Network representation of Chr-associated phosphosites mapped to adhesion- and stress-associated signaling modules based on the annotation-enrichment analysis. Data are shown as mean ± standard deviation (SD) from three independent experiments. Statistical significance was determined using an unpaired two-tailed Student’s t-test; #p<0.05; *p<0.01.

    Article Snippet: Parental 786-O and Caki-1 renal cell carcinoma cell lines were obtained from ATCC (Manassas, VA, USA) and cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum at 37°C in a humidified atmosphere containing 5% CO 2 .

    Techniques: Migration, Transwell Migration Assay, Staining, Invasion Assay, Incubation, Western Blot, Control, Standard Deviation, Two Tailed Test